Oxford Immunotec Global (OXFD) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Oxford Immunotec Global (NASDAQ: OXFD) in the last few weeks:

  • 5/18/2019 – Oxford Immunotec Global was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/15/2019 – Oxford Immunotec Global was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 5/7/2019 – Oxford Immunotec Global was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/2/2019 – Oxford Immunotec Global was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/30/2019 – Oxford Immunotec Global was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 4/30/2019 – Oxford Immunotec Global was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/24/2019 – Oxford Immunotec Global was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/23/2019 – Oxford Immunotec Global was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/17/2019 – Oxford Immunotec Global was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/16/2019 – Oxford Immunotec Global was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/16/2019 – Oxford Immunotec Global was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $17.00 price target on the stock. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/5/2019 – Oxford Immunotec Global was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/5/2019 – Oxford Immunotec Global was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/4/2019 – Oxford Immunotec Global was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “
  • 4/1/2019 – Oxford Immunotec Global was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 3/26/2019 – Oxford Immunotec Global was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

NASDAQ:OXFD opened at $14.85 on Thursday. The stock has a market cap of $396.95 million, a P/E ratio of 29.12 and a beta of 0.32. Oxford Immunotec Global PLC has a 52-week low of $11.66 and a 52-week high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. The firm had revenue of $14.79 million for the quarter, compared to analyst estimates of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. Oxford Immunotec Global’s revenue was up 26.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. Sell-side analysts anticipate that Oxford Immunotec Global PLC will post -0.28 earnings per share for the current fiscal year.

In related news, SVP Elizabeth M. Keiley sold 4,100 shares of Oxford Immunotec Global stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $17.00, for a total transaction of $69,700.00. Following the transaction, the senior vice president now directly owns 26,928 shares of the company’s stock, valued at $457,776. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total value of $48,150.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $48,150. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,700 shares of company stock worth $294,658. 6.61% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Morgan Stanley grew its holdings in shares of Oxford Immunotec Global by 238.7% during the 1st quarter. Morgan Stanley now owns 331,731 shares of the company’s stock worth $5,715,000 after purchasing an additional 233,797 shares in the last quarter. Man Group plc grew its holdings in shares of Oxford Immunotec Global by 105.6% during the 1st quarter. Man Group plc now owns 356,624 shares of the company’s stock worth $6,145,000 after purchasing an additional 183,181 shares in the last quarter. Coastal Investment Advisors Inc. acquired a new stake in shares of Oxford Immunotec Global during the 1st quarter worth approximately $35,000. Wellington Management Group LLP grew its holdings in shares of Oxford Immunotec Global by 22.5% during the 1st quarter. Wellington Management Group LLP now owns 264,248 shares of the company’s stock worth $4,553,000 after purchasing an additional 48,598 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Oxford Immunotec Global during the 1st quarter worth approximately $1,185,000. Institutional investors and hedge funds own 91.14% of the company’s stock.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

See Also: Understanding Options Trading

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply